
    
      Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic
      benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular
      carcinoma. The results will be compared to placebo. The trial duration is 3 months and will
      consist of one stage with baseline laboratory evaluation including AFP levels with follow-up
      at monthly intervals. In addition pre-entry abdominal CT scan and end-study CT scan will be
      preformed. The clinical evaluation will be quantified according to special performance
      questionnaire.
    
  